Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Marin, David  [Clear All Filters]
2019
Chamoun, K., Milton, D.R., Ledesma, C., Young, K.H., Jabbour, E.J., Alatrash, G., Anderlini, P., Bashir, Q., Ciurea, S.O., Marin, D., et al. (2019). Allogeneic Transplantation after Myeloablative Rituximab/BEAM +/- Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-up Results.Biol Blood Marrow Transplant.
Li, L., Chen, H., Marin, D., Xi, Y., Miao, Q., Lv, J., Banerjee, P.Prosad, Shaim, H., Daher, M., Basar, R., et al. (2019). A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation.Blood Adv3, 4117-4130.
2018
Veltri, L., Rezvani, K., Oran, B., Mehta, R., Rondon, G., Kebriaei, P., Popat, U., Nieto, Y., Hosing, C., Qazilbash, M., et al. (2018). Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia.Biol Blood Marrow Transplant.
2016
Kebriaei, P., Singh, H., M Huls, H., Figliola, M.J., Bassett, R., Olivares, S., Jena, B., Dawson, M.J., Kumaresan, P.R., Su, S., et al. (2016). Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest.
Gaballa, S., Ge, I., Fakih, R.El, Brammer, J.E., Kongtim, P., Tomuleasa, C., Wang, S.A., Lee, D., Petropoulos, D., Cao, K., et al. (2016). Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Cancer.
Brammer, J.E., Khouri, I., Marin, D., Ledesma, C., Rondon, G., Ciurea, S.O., Nieto, Y., Champlin, R.E., Hosing, C., and Kebriaei, P. (2016). Stem cell transplantation outcomes in lymphoblastic lymphoma.Leuk Lymphoma1-6.